All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
ALLG AMLM16: Does sorafenib plus intensive chemotherapy improve outcome in FLT3-ITD AML?
Featured:
Andrew Wei
Natasha S. AnsteeDuring the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Andrew Wei, The Alfred Hospital, Melbourne, AU, and Natasha S. Anstee, The Alfred Hospital & Monash University, Melbourne, AU. We asked, Does sorafenib plus intensive chemotherapy improve outcome in FLT3-internal tandem duplication (FLT3-ITD) AML?
ALLG AMLM16: Does sorafenib plus intensive chemotherapy improve outcome in FLT3-ITD AML?
Wei starts by introducing the clinical study data from AMLM16, a randomized, placebo-controlled trial evaluating sorafenib versus placebo in combination with intensive chemotherapy for previously untreated adult patients with FLT3-ITD AML. In this study, sorafenib did not improve event-free survival when combined with intensive chemotherapy; Wei discusses the possible causes of this result and the subgroups that did better in the sorafenib arm. Anstee then reports the results from the correlative studies evaluating the impact of sorafenib on phospho-FLT3 inhibition and the presence of FLT3-ITD measurable residual disease after chemotherapy.